GlassScriptPhysician profile
Pouya Bahrami
NPI 1871526301
$3,477.60
in general payments reported to CMS, 2019-2025
31 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $36.95 · 2021: $35.43 · 2022: $208 · 2023: $604 · 2024: $969 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,253 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.36 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $836.17 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $536.89 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $242.05 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Allergan, INC. | $209.01 | 2019-2020 | |
| Mannkind Corporation | $183.85 | 2023-2025 | Afrezza |
| Boston Scientific Corporation | $157.97 | 2024 | |
| Sumitomo Pharma America, INC. | $139.35 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $123.12 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.51 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $91.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $83.98 | 2019 | |
| Valeritas, INC. | $68.67 | 2019 | |
| Astellas Pharma US INC | $61.85 | 2019-2023 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.48 | 2024 | Caplyta |
| Alkermes, INC. | $58.89 | 2024 | Lybalvi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $57.03 | 2024-2025 | |
| Smith+Nephew, INC. | $56.53 | 2024-2025 | Collagenase Santyl |
| Pfizer INC. | $44.05 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $40.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.57 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $37.36 | 2024 | Hetlioz, Fanapt |
| Integra Lifesciences Corporation | $34.52 | 2022 | |
| Axsome Therapeutics, INC. | $31.28 | 2023 | Auvelity |
| Dexcom, INC. | $28.46 | 2022 | |
| Phathom Pharmaceuticals, INC. | $25.38 | 2024 | Voquezna |
| Livanova USA, INC. | $22.70 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Abbott Laboratories | $21.51 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $20.24 | 2025 | Shingrix, Arexvy |
| Sunovion Pharmaceuticals INC. | $17.96 | 2019 | |
| Amgen INC. | $15.18 | 2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $13.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pouya Bahrami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.